Skip to content

Facal microbiota transplantation in patients with liver cirrhosis ascites efficacy and safety evaluation

Facal microbiota transplantation in patients with liver cirrhosis ascites efficacy and safety evaluation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034096
Enrollment
Unknown
Registered
2020-06-23
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

The treatment group:Facal microbiota transplantation

Sponsors

Mianyang Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The patients who met the diagnostic criteria of ascites due to cirrhosis had no improvement in the condition of the last one who received routine treatment of liver protection, diuresis and nutritional support. 2. Patients who agree to participate in the clinical study and sign the informed consent can receive the follow-up visit, follow-up and specimen collection on time; 3. Patients aged 18-85 years with unlimited gender and follow-up time longer than 3 months; 4. Those patients who are suitable for gastroenteroscopy and FMT.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Drug addicts; 3. Suspected or diagnosed patients with a history of alcohol / drug abuse; 4. Patients with a large history of abdominal surgery; 5. Patients with diseases that may cause gastrointestinal function damage. Such as diabetes, thyroid disease, intestinal obstruction, inflammatory bowel disease (IBD), etc; 6. Patients who took antibiotics, non steroidal anti-inflammatory drugs, microecological agents, gastrointestinal motility drugs, acid suppressants and other drugs that affected intestinal flora 2 weeks before treatment; 7. 2 weeks ago, patients with gastrointestinal bleeding or spontaneous bacterial peritonitis (SBP); 8. Patients with other serious diseases that may affect their survival (including serious infection, serious heart, kidney, respiratory, blood, endocrine, neuropsychiatric and other diseases) or with other types of tumors; 9. Patients who have a history of using immunosuppressants or other serious immunodeficiency diseases, such as human acquired immunodeficiency virus (HIV) infection, rheumatic diseases, etc..

Design outcomes

Primary

MeasureTime frame
Clinical symptoms;Liver function;ascites;Changes of intestinal flora;

Countries

China

Contacts

Public ContactLi Xiao'an

Mianyang Central Hospital

435445611@qq.com+86 13880868858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026